ArticleVirchows Archiv : an international journal of pathology2026
Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Female genital tract lesions with putative prostatic differentiation include vaginal tubulosquamous polyp (TSP), cervical ectopic prostatic tissue (EPT), and adenoid basal carcinoma (ABC). HoxB13 is a transcription factor specific for the prostate, not previously assessed in these lesions. A cohort of 13 TSPs, 6 EPTs, 17 ABCs, and 8 adenoid basal hyperplasia (ABH) was analyzed for expression of prostatic markers HoxB13, NKX3.1, p16, and androgen receptor (AR). Additional 28 cervical high-grade squamous intraepithelial lesions (HSILs), 21 cervical squamous cell carcinomas (SCCs), 19 endocervical adenocarcinomas (EACs), and 10 endometrial endometrioid adenocarcinomas (ECs) were included. The results were recorded as immunoreactive score (IRS). In TSPs and EPTs, HoxB13 and NKX3.1 were positive in 100% and 89.5% of cases, respectively. No HoxB13, NKX3.1, and p16 was observed in ABHs. In contrast, all ABCs showed diffuse p16 positivity. NKX3.1 was positive in 82.6% of ABCs (median IRS = 2), HoxB13 was positive in 100% of ABCs (median IRS = 8), and the difference was statistically significant (p < 0.001). Both HoxB13 and NKX3.1 were positive in 9.5% (2/21) SCCs and 21.1% (4/19) EACs. Additionally, 40% (4/10) ECs were HoxB13-positive (IRS = 1-2). Any positivity of HoxB13 was 80% specific and 100% sensitive for the ABC. NKX3.1 was only 82.4% sensitive, but 88% specific for the diagnosis of ABC. Additionally, HoxB13 was also seen in 29.8% HSILs. No ABC showed AR positivity, while this was observed in rare cells (IRS 1-2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.